Abbott 3Q profit falls on Solvay, Meridia costs

(AP) -- Drug and medical device maker Abbott Laboratories said Wednesday its third-quarter net income dropped 40 percent on costs connected with its purchase of Solvay Pharmaceuticals and its decision to withdraw the diet drug Meridia from the U.S. and Canadian markets.

Read the whole article on Physorg

More from Physorg